Deutsch English Français

Contact

EP0667901

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP0667901

EP0667901 - NOVEL CYTOKINE [Right-click to bookmark this link]
Status	Patent maintained as amended Status updated on 12.09.2008 Database last updated on 19.07.2024
Most recent event Tooltip	12.09.2008	Patent maintained (B2 publication)	published on 15.10.2008 [2008/42]
Applicant(s)	For all designated states Immunex Corporation One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US
	[N/P]
Former [2008/42]	For all designated states IMMUNEX CORPORATION One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US
Former [2004/48]	For all designated states Immunex Corporation One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US
Former [1995/34]	For all designated states IMMUNEX CORPORATION 51 University Street Seattle Washington 98101 / US
Inventor(s)	01 / Armitage Richard J. 5133 Eagle Harbor Drive, Bainbrigde Island WA 98110 / US
	02 / Fanslow William C. 32204 22nd Avenue Southwest Federal Way, WA 98023 / US
	03 / Spriggs Melanie K. 2256 12th Avenue West, Seattle WA 98119 / US
	04 / Subhashini, Srinivasan 11325 NE 129th Street Kirkland, WA 98034 / US
	[1998/43]
Former [1995/34]	01 / Subhashini, Srinivasan 11325 NE 129th Street Kirkland, WA 98034 / US
Representative(s)	Lee, Nicholas John, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	[N/P]
Former [2006/08]	Lee, Nicholas John, et al Kilburn & Strode, 20 Red Lion Street London WC1R 4PJ / GB
Former [2000/11]	Chapman, Paul William, et al Kilburn & Strode, 20 Red Lion Street London WC1R 4PJ / GB
Former [1995/34]	Sheard, Andrew Gregory, et al Kilburn & Strode 30, John Street London WC1N 2DD / GB
Application number, filing date	92925017.3	23.10.1992
	[1995/34]
	WO1992US08990
Priority number, date	US19910783707	25.10.1991 Original published format: US 783707
	US19910805723	05.12.1991 Original published format: US 805723
	[1995/34]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO9308207
	Date:	29.04.1993
	[1993/11]
	Type:	A1 Application with search report
	No.:	EP0667901
	Date:	23.08.1995
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 29.04.1993 takes the place of the publication of the European patent application.
	[1995/34]
	Type:	B1 Patent specification
	No.:	EP0667901
	Date:	18.08.2004
	Language:	EN
	[2004/34]
	Type:	B2 New European patent specification
	No.:	EP0667901
	Date:	15.10.2008
	Language:	EN
	[2008/42]
Search report(s)	International search report - published on:	US	08.07.1993
	(Supplementary) European search report - dispatched on:	EP	22.06.1995
Classification	IPC:	C12N15/12, C07K14/00, A61K38/16, A61K38/19, C12P21/08	[2004/11]
	CPC:	C07K16/2875 (EP); A61P29/00 (EP); A61P37/00 (EP); A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP); (+) C07K14/70575 (EP); C12N15/62 (EP); A61K38/00 (EP); C07K2317/34 (EP); C07K2319/00 (EP); C07K2319/02 (EP); C07K2319/03 (EP); C07K2319/30 (EP); C07K2319/32 (EP); C07K2319/73 (EP); C07K2319/74 (EP); C07K2319/75 (EP) (-)
	Former IPC [1995/34]	C12N15/12, C07K13/00, A61K37/02, C12P21/08
Designated contracting states	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE [1995/34]
Title	German:	NEUE CYTOKINE	[1995/34]
	English:	NOVEL CYTOKINE	[1995/34]
	French:	NOUVELLE CYTOKINE	[1995/34]
Entry into regional phase	28.04.1994	National basic fee paid
	28.04.1994	Search fee paid
	28.04.1994	Designation fee(s) paid
	28.04.1994	Examination fee paid
Examination procedure	03.05.1993	Request for preliminary examination filed International Preliminary Examining Authority: DE
	28.04.1994	Examination requested [1995/34]
	27.06.1997	Despatch of a communication from the examining division (Time limit: M06)
	05.12.1997	Reply to a communication from the examining division
	20.07.2000	Despatch of a communication from the examining division (Time limit: M04)
	29.11.2000	Reply to a communication from the examining division
	25.03.2002	Despatch of a communication from the examining division (Time limit: M06)
	11.11.2002	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	11.12.2002	Reply to a communication from the examining division
	13.01.2003	Despatch of a communication from the examining division (Time limit: M06)
	11.07.2003	Reply to a communication from the examining division
	04.08.2003	Despatch of a communication from the examining division (Time limit: M04)
	08.12.2003	Reply to a communication from the examining division
	12.02.2004	Communication of intention to grant the patent
	10.06.2004	Fee for grant paid
	10.06.2004	Fee for publishing/printing paid
Divisional application(s)	EP98113461.2 / EP0897983
Opposition(s)	Opponent(s)	01 18.05.2005 ADMISSIBLE BIOGEN IDEC MA INC. 14 Cambridge Center Cambridge, Massachusetts, MA 02142 / US Opponent's representative Mercer, Christopher Paul Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
		[N/P]
	Former [2005/29]
	Opponent(s)	01 18.05.2005 ADMISSIBLE Biogen Idec MA Inc. 14 Cambridge Center Cambridge, Massachusetts, MA 02142 / US Opponent's representative Mercer, Christopher Paul Carpmaels & Ransford 43, Bloomsbury Square London WC1A 2RA / GB
	15.07.2005	Invitation to proprietor to file observations on the notice of opposition
	21.04.2006	Reply of patent proprietor to notice(s) of opposition
	29.10.2007	Cancellation of oral proceeding that was planned for 16.11.2007
	29.10.2007	Despatch of minutes of oral proceedings
	16.11.2007	Date of oral proceedings
	07.01.2008	Despatch of interlocutory decision in opposition
	17.01.2008	Legal effect of interlocutory decision in opposition
	02.06.2008	Despatch of communication that the patent will be maintained as amended
	29.08.2008	Fee for printing new specification paid
Request for further processing for:	11.12.2002	Request for further processing filed
	13.12.2002	Full payment received (date of receipt of payment) Request granted
	02.01.2003	Decision despatched
Fees paid	Renewal fee
	08.10.1994	Renewal fee patent year 03
	10.10.1995	Renewal fee patent year 04
	09.10.1996	Renewal fee patent year 05
	10.10.1997	Renewal fee patent year 06
	12.10.1998	Renewal fee patent year 07
	14.10.1999	Renewal fee patent year 08
	11.10.2000	Renewal fee patent year 09
	11.10.2001	Renewal fee patent year 10
	15.10.2002	Renewal fee patent year 11
	14.10.2003	Renewal fee patent year 12
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[E]EP0555880 (BRISTOL MYERS SQUIBB CO [US], et al) [E] 13-17* the whole document *;
		[E]EP0585943 (BRISTOL MYERS SQUIBB CO [US]) [E] 1-19 * the whole document *;
		[A] - CLARK, "CD40:A CYTOKINE RECEPTOR IN SEARCH OF A LIGAND", TISSUE ANTIGENS, COPENHAGEN, vol. 35, pages 33 - 36 [A] 1-19 * the whole document *
		[A] - MALLETT ET AL, "A NEW SUPERFAMILY OF CELL SURFACE PROTEINS RELATED TO THE NERVE GROWTH FACTOR RECEPTOR", IMMUNOLOGY TODAY, AMSTERDAM, vol. 12, no. 7, doi:doi:10.1016/0167-5699(91)90033-P, pages 220 - 223, XP023943720 [A] 1-19 * the whole document * DOI: http://dx.doi.org/10.1016/0167-5699(91)90033-P
		[DA] - GASCAN ET AL, "ANTI-CD40 MONOCLONAL ANTIBODIES OR CD4+ T CELL CLONES AND IL-4 INDUCE IGG4 AND IGE SWITCHING IN PURIFIED HUMAN B CELLS VIA DIFFERENT SIGNALING PATHWAYS", THE JOURNAL OF IMMUNOLOGY, BALTIMORE,USA, (19910701), vol. 147, no. 1, pages 8 - 13 [DA] 13 * the whole document *
		[PX] - ARMITAGE ET AL, "MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A MURINE LIGAND FOR CD40", NATURE, LONDON,GB, (19920507), vol. 357, doi:doi:10.1038/357080a0, pages 80 - 82, XP002024662 [PX] 1-19 * the whole document * DOI: http://dx.doi.org/10.1038/357080a0
		[PX] - NOELLE ET AL, "A 39-KDA PROTEIN ON ACTIVATED HELPER T CELLS BINDS CD40 AND TRANSDUCES THE SIGNAL FOR COGNATE ACTIVATION OF B CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES,USA, WASHINGTON D.C.,USA, vol. 89, doi:doi:10.1073/pnas.89.14.6550, pages 6550 - 6554, XP002941549 [PX] 13-17 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.89.14.6550
		[PX] - FANSLOW ET AL, "SOLUBLE FORMS OF CD40 INHIBIT BIOLOGIC RESPONSES OF HUMAN B CELLS", THE JOURNAL OF IMMUNOLOGY, BALTIMORE,USA, (19920715), vol. 149, no. 2, pages 655 - 660, XP002017167 [PX] 13 * the whole document *
	International search	[A] - Nature, Volume 350, issued 04 April 1991, M.L. RIORDAN et al., "Oligonucleotide-Based Therapeutics", pages 442-443, entire document.
		[Y] - The EMBO Journal, Volume 8(5), issued 1989, I. STAMENKOVIC et al., "A B-Lymphocyte Activation Molecule Related to the Nerve Growth Factor Receptor and Induced by Cytokines in Carcinomas", pages 1403-1410, entire document, especially page 1408, 2nd column, paragraphs 2-3.
		[Y] - Proceedings of the National Academy of Science, Vol. 84, issued December 1987, A. ARUFFO and B. SEED, "Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System", pages 8573-8577, entire document, see especially page 8573, paragraph 2.

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p